Iovance Shares Surge 34% Following Strong Q3 Earnings and Robust Amtagvi Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Should l Buy IOVA?
Source: SeekingAlpha
Q3 Financial Performance: Iovance Biotherapeutics saw a ~34% increase in stock price after reporting Q3 results that exceeded expectations, driven by strong sales of its T-cell immunotherapy Amtagvi, which generated $58M in revenue.
Revenue Guidance: The company reaffirmed its 2025 revenue guidance of $250M-$300M, with consensus estimates at $266.68M, reflecting optimism for the first full year of Amtagvi sales.
Treatment Center Expansion: Iovance has expanded to 80 authorized treatment centers across approximately 40 states, with an average therapy delivery turnaround time of 28 days.
Financial Position: As of September 30, Iovance reported a GAAP net loss of (0.25) and ended the quarter with ~$307M in cash and equivalents, down from ~$330M at the end of 2024.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IOVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IOVA
Wall Street analysts forecast IOVA stock price to rise
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 2.520
Low
1.50
Averages
9.50
High
17.00
Current: 2.520
Low
1.50
Averages
9.50
High
17.00
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iovance Biotherapeutics Unveils New Data on Amtagvi Therapy
- Significant Clinical Efficacy: Iovance Biotherapeutics reported that commercial Amtagvi® achieved a 44% objective response rate (ORR) and a 73% disease control rate in 41 previously treated advanced melanoma patients, showcasing its outstanding performance in real-world settings and potentially transforming the treatment landscape for advanced melanoma.
- Early Treatment Advantage: The data revealed that patients receiving two or fewer lines of therapy had an ORR of 52%, compared to only 33% for those with three or more lines, indicating that early administration of Amtagvi significantly enhances patient response, underscoring the importance of timely intervention.
- FDA Accelerated Approval Context: Amtagvi received FDA accelerated approval in February 2024 based on the ORR and duration of response (DOR) from the C-144-01 clinical trial, with the new real-world data showing an ORR of 31%, highlighting the clinical relevance of these findings and potentially driving broader clinical adoption.
- Market Demand and Outlook: With over 8,000 annual deaths from advanced melanoma in the U.S. and more than half of patients progressing within 12 months of standard care, the successful application of Amtagvi not only addresses an unmet medical need but also presents significant market opportunities for Iovance.
See More
Iovance Biotherapeutics Stock Sentiment and Revenue Outlook
- Retail Sentiment Remains Bullish: Over the past 24 hours, retail sentiment around Iovance (IOVA) stock on Stocktwits has stayed in the ‘bullish’ territory, with message volume at ‘high’ levels, indicating strong investor confidence in the company's future developments.
- Significant Revenue Growth: For the three months ending September, Iovance reported total product revenue of $68 million, including $58 million from Amtagvi sales in the U.S., highlighting the company's robust performance in the tumor immunotherapy market.
- Optimistic 2025 Revenue Outlook: Iovance expects full-year 2025 revenue to range between $250 million and $300 million, marking the first full calendar year of Amtagvi sales, with analysts forecasting an average revenue of $259.45 million, reflecting market anticipation for its products.
- Stock Price Volatility and Acquisition Rumors: Despite an 8% rise in IOVA shares on Monday, the stock has fallen 54% over the past 12 months, with investors expressing concern over management's potential discussions with Merck, which could impact future acquisition opportunities.
See More
Iovance Biotherapeutics Grants 97,710 Stock Options to Attract New Employees
- Stock Option Grant: On January 15, 2026, Iovance Biotherapeutics approved the grant of a total of 97,710 stock options to 17 new non-executive employees, aimed at attracting and retaining talent, thereby enhancing the company's competitiveness in the tumor immunotherapy sector.
- Exercise Price Setting: Each stock option has an exercise price of $2.22, which matches the closing price of Iovance's common stock on the grant date, a pricing strategy that helps incentivize employees to grow alongside the company and enhances their sense of belonging.
- Vesting Schedule: The stock options will vest over three years, with one-third vesting on the first anniversary of the employee's start date and the remaining shares vesting in quarterly installments over the next two years, ensuring long-term employee commitment aligns with the company's growth.
- Incentive Plan Background: This grant is made under Iovance's inducement plan established in 2021 and amended multiple times, complying with Nasdaq listing rules, reflecting the company's commitment to talent acquisition and its ongoing strategic development in the biotechnology industry.
See More
Iovance and Others Face Shareholder Lawsuits Seeking Governance Reforms
- Shareholder Lawsuit Background: Iovance Biotherapeutics is facing a securities class action lawsuit from shareholders alleging that it failed to disclose significant misleading information regarding the commercial demand and revenue potential of its lead therapy, Amtagvi, resulting in investor losses.
- Governance Reform Opportunity: Shareholders who held Iovance shares continuously since before May 9, 2024, may seek governance reforms related to internal controls, transparency, and executive oversight, with successful claimants potentially eligible for incentive awards subject to court approval.
- Nutex Health Allegations: Nutex Health is similarly facing shareholder lawsuits, accused of overstating revenue from arbitration-related claims and failing to disclose material weaknesses in internal accounting controls, which led to financial results not being prepared in accordance with GAAP, impacting investor confidence.
- Molina Healthcare Issues: Molina Healthcare has also been accused of making misleading statements regarding medical cost trends and financial outlook, failing to disclose that medical cost pressures were materially higher than represented, potentially leading to governance reform opportunities for its shareholders.
See More
Intellia and Iovance Stocks Plummet, Analysts See Potential Upside
- Intellia Stock Decline: Intellia Therapeutics' stock has dropped 19% due to clinical trial issues, leading to cautious market sentiment, although analysts' price target of $22.43 suggests a potential upside of 139%.
- Iovance Revenue Growth: Iovance Biotherapeutics' Amtagvi product generated $176.7 million in revenue in the first nine months of 2025, nearly doubling year-over-year, indicating strong market demand potential.
- Regulatory Challenges: Intellia's nex-z treatment was placed on clinical hold due to a patient death during trials, creating significant pressure on the stock, and the company now awaits further decisions from the FDA regarding its future.
- Iovance Profitability Outlook: Despite the revenue growth from Amtagvi, the complex and costly production process leaves Iovance's path to profitability unclear, leading analysts to view a 191% stock increase as highly unlikely.
See More
Intellia and Iovance Face Major Challenges as Stocks Plummet
- Intellia's Clinical Setback: Intellia Therapeutics faced a clinical hold on its candidate nex-z due to a participant's death, resulting in a 19% stock decline, highlighting significant risks and uncertainties in the gene editing sector.
- Iovance's Revenue Growth: Despite Iovance Biotherapeutics' Amtagvi generating $176.7 million in revenue in the first nine months of 2025, nearly doubling year-over-year, the stock has plummeted 61% due to production complexities and unclear profitability pathways, reflecting market concerns about its future.
- Market Potential Assessment: Intellia's nex-z targets approximately 50,000 hereditary transthyretin amyloidosis patients, while the wild type could affect 200,000 to 500,000, indicating substantial market potential, yet achieving clinical and regulatory milestones remains uncertain.
- Investment Risk Advisory: Although analysts suggest that Intellia and Iovance stocks are undervalued at current levels, the significant clinical and commercial challenges each faces warrant caution for long-term investors, particularly as Intellia's stock may struggle to achieve a 139% rise in the coming year.
See More
Iovance Biotherapeutics Unveils New Data on Amtagvi Therapy
- Significant Clinical Efficacy: Iovance Biotherapeutics reported that commercial Amtagvi® achieved a 44% objective response rate (ORR) and a 73% disease control rate in 41 previously treated advanced melanoma patients, showcasing its outstanding performance in real-world settings and potentially transforming the treatment landscape for advanced melanoma.
- Early Treatment Advantage: The data revealed that patients receiving two or fewer lines of therapy had an ORR of 52%, compared to only 33% for those with three or more lines, indicating that early administration of Amtagvi significantly enhances patient response, underscoring the importance of timely intervention.
- FDA Accelerated Approval Context: Amtagvi received FDA accelerated approval in February 2024 based on the ORR and duration of response (DOR) from the C-144-01 clinical trial, with the new real-world data showing an ORR of 31%, highlighting the clinical relevance of these findings and potentially driving broader clinical adoption.
- Market Demand and Outlook: With over 8,000 annual deaths from advanced melanoma in the U.S. and more than half of patients progressing within 12 months of standard care, the successful application of Amtagvi not only addresses an unmet medical need but also presents significant market opportunities for Iovance.
See More
Iovance Biotherapeutics Stock Sentiment and Revenue Outlook
- Retail Sentiment Remains Bullish: Over the past 24 hours, retail sentiment around Iovance (IOVA) stock on Stocktwits has stayed in the ‘bullish’ territory, with message volume at ‘high’ levels, indicating strong investor confidence in the company's future developments.
- Significant Revenue Growth: For the three months ending September, Iovance reported total product revenue of $68 million, including $58 million from Amtagvi sales in the U.S., highlighting the company's robust performance in the tumor immunotherapy market.
- Optimistic 2025 Revenue Outlook: Iovance expects full-year 2025 revenue to range between $250 million and $300 million, marking the first full calendar year of Amtagvi sales, with analysts forecasting an average revenue of $259.45 million, reflecting market anticipation for its products.
- Stock Price Volatility and Acquisition Rumors: Despite an 8% rise in IOVA shares on Monday, the stock has fallen 54% over the past 12 months, with investors expressing concern over management's potential discussions with Merck, which could impact future acquisition opportunities.
See More
Iovance Biotherapeutics Grants 97,710 Stock Options to Attract New Employees
- Stock Option Grant: On January 15, 2026, Iovance Biotherapeutics approved the grant of a total of 97,710 stock options to 17 new non-executive employees, aimed at attracting and retaining talent, thereby enhancing the company's competitiveness in the tumor immunotherapy sector.
- Exercise Price Setting: Each stock option has an exercise price of $2.22, which matches the closing price of Iovance's common stock on the grant date, a pricing strategy that helps incentivize employees to grow alongside the company and enhances their sense of belonging.
- Vesting Schedule: The stock options will vest over three years, with one-third vesting on the first anniversary of the employee's start date and the remaining shares vesting in quarterly installments over the next two years, ensuring long-term employee commitment aligns with the company's growth.
- Incentive Plan Background: This grant is made under Iovance's inducement plan established in 2021 and amended multiple times, complying with Nasdaq listing rules, reflecting the company's commitment to talent acquisition and its ongoing strategic development in the biotechnology industry.
See More
Iovance and Others Face Shareholder Lawsuits Seeking Governance Reforms
- Shareholder Lawsuit Background: Iovance Biotherapeutics is facing a securities class action lawsuit from shareholders alleging that it failed to disclose significant misleading information regarding the commercial demand and revenue potential of its lead therapy, Amtagvi, resulting in investor losses.
- Governance Reform Opportunity: Shareholders who held Iovance shares continuously since before May 9, 2024, may seek governance reforms related to internal controls, transparency, and executive oversight, with successful claimants potentially eligible for incentive awards subject to court approval.
- Nutex Health Allegations: Nutex Health is similarly facing shareholder lawsuits, accused of overstating revenue from arbitration-related claims and failing to disclose material weaknesses in internal accounting controls, which led to financial results not being prepared in accordance with GAAP, impacting investor confidence.
- Molina Healthcare Issues: Molina Healthcare has also been accused of making misleading statements regarding medical cost trends and financial outlook, failing to disclose that medical cost pressures were materially higher than represented, potentially leading to governance reform opportunities for its shareholders.
See More
Intellia and Iovance Stocks Plummet, Analysts See Potential Upside
- Intellia Stock Decline: Intellia Therapeutics' stock has dropped 19% due to clinical trial issues, leading to cautious market sentiment, although analysts' price target of $22.43 suggests a potential upside of 139%.
- Iovance Revenue Growth: Iovance Biotherapeutics' Amtagvi product generated $176.7 million in revenue in the first nine months of 2025, nearly doubling year-over-year, indicating strong market demand potential.
- Regulatory Challenges: Intellia's nex-z treatment was placed on clinical hold due to a patient death during trials, creating significant pressure on the stock, and the company now awaits further decisions from the FDA regarding its future.
- Iovance Profitability Outlook: Despite the revenue growth from Amtagvi, the complex and costly production process leaves Iovance's path to profitability unclear, leading analysts to view a 191% stock increase as highly unlikely.
See More
Intellia and Iovance Face Major Challenges as Stocks Plummet
- Intellia's Clinical Setback: Intellia Therapeutics faced a clinical hold on its candidate nex-z due to a participant's death, resulting in a 19% stock decline, highlighting significant risks and uncertainties in the gene editing sector.
- Iovance's Revenue Growth: Despite Iovance Biotherapeutics' Amtagvi generating $176.7 million in revenue in the first nine months of 2025, nearly doubling year-over-year, the stock has plummeted 61% due to production complexities and unclear profitability pathways, reflecting market concerns about its future.
- Market Potential Assessment: Intellia's nex-z targets approximately 50,000 hereditary transthyretin amyloidosis patients, while the wild type could affect 200,000 to 500,000, indicating substantial market potential, yet achieving clinical and regulatory milestones remains uncertain.
- Investment Risk Advisory: Although analysts suggest that Intellia and Iovance stocks are undervalued at current levels, the significant clinical and commercial challenges each faces warrant caution for long-term investors, particularly as Intellia's stock may struggle to achieve a 139% rise in the coming year.
See More
